The formulation comparison between a biosimilar and a branded biologic. The cost, availability, and supply chain benefits of ...

Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of ...

Introduction Biosimilar monoclonal antibodies (mAbs) are biologic drugs designed to be highly similar to already approved reference monoclonal ...

The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...

I Gedeon Richter Plc. announces today that the European Medicines Agency has accepted Richter’s marketing authorization application (MAA) for ...

LAKE ZURICH, IL, USA I March 27, 2025 I Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence® ...

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Samsung Bioepis and Hanmi Pharmaceutical will jointly sell the osteoporosis treatment Prolia biosimilar (a copy of a biopharmaceutical) in the domestic market. Samsung Bioepis, the developer of ...

Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025, at 8:00 am ET (12:00pm ...

Bio-Thera and Dr. Reddy's partner for biosimilar commercialization in Southeast Asia, expanding access to affordable ...

Biosimilars, approved copies of these biological medications, are high quality, similar, and less expensive medicines than the reference biologic and can play an important role in addressing this ...

Looking further ahead, NHS England envisages savings as a whole from biosimilars of some £400 - £500 million per year by 2021, if it can increase uptake of ‘best value biologic medicines’.